leadf
logo-loader
viewBioPorto

BioPorto Diagnostics A/S is helping develop a ten-minute coronavirus test that could be on the market by the year-end

This potentially ground-breaking technology is being developed in harness with the University of Southern Denmark, which brings to the party its antibody expertise

BioPorto -
Chief medical officer Christopher Bird will present at the Proactive Virtual Forum on Tuesday October 27

BioPorto Diagnostics A/S (CPH:BIOPOR) shares have almost doubled in value in little over a month, reflecting the progress it has made with its ten-minute COVID-19 test.

This potentially ground-breaking technology is being developed in harness with the University of Southern Denmark, which brings to the party its antibody expertise.

If successful, the company intends to file for fast-track emergency use in the US along and is pursuing official sign-off for the device in Europe too.

All of this means BioPorto could have its ten-minute test out on the market by the end of the year.

Chief medical officer Christopher Bird will explain all when he presents to the Proactive Virtual Forum on Tuesday October 27, from 1pm EST.

CLICK HERE TO REGISTER

About the event:

  • Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
  • We look beyond the numbers and meet the people creating the value for shareholders

The format:

  • Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
  • You can watch the event afterwards on our YouTube channel

CLICK HERE TO REGISTER

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read